AAAAAA

   
Results: 1-9 |
Results: 9
USE OF HETEROLOGOUSLY EXPRESSED HUMAN CYTOCHROME-P450 1A2 TO PREDICT TACRINE-FLUVOXAMINE DRUG-INTERACTION IN MAN
Authors: BECQUEMONT L LEBOT MA RICHE C FUNCKBRENTANO C JAILLON P BEAUNE P
Citation: L. Becquemont et al., USE OF HETEROLOGOUSLY EXPRESSED HUMAN CYTOCHROME-P450 1A2 TO PREDICT TACRINE-FLUVOXAMINE DRUG-INTERACTION IN MAN, Pharmacogenetics, 8(2), 1998, pp. 101-108
GLUTATHIONE-S-TRANSFERASE-THETA GENETIC-POLYMORPHISM MIGHT INFLUENCE TACRINE HEPATOTOXICITY IN ALZHEIMERS PATIENTS
Authors: BECQUEMONT L LECOEUR S SIMON T BEAUNE P FUNCKBRENTANO C JAILLON P
Citation: L. Becquemont et al., GLUTATHIONE-S-TRANSFERASE-THETA GENETIC-POLYMORPHISM MIGHT INFLUENCE TACRINE HEPATOTOXICITY IN ALZHEIMERS PATIENTS, Pharmacogenetics, 7(3), 1997, pp. 251-253
INHIBITION BY OMEPRAZOLE OF PROGUANIL METABOLISM - MECHANISM OF THE INTERACTION IN-VITRO AND PREDICTION OF IN-VIVO RESULTS FROM THE IN-VITRO EXPERIMENTS
Authors: FUNCKBRENTANO C BECQUEMONT L LENEVEU A ROUX A JAILLON P BEAUNE P
Citation: C. Funckbrentano et al., INHIBITION BY OMEPRAZOLE OF PROGUANIL METABOLISM - MECHANISM OF THE INTERACTION IN-VITRO AND PREDICTION OF IN-VIVO RESULTS FROM THE IN-VITRO EXPERIMENTS, The Journal of pharmacology and experimental therapeutics, 280(2), 1997, pp. 730-738
INFLUENCE OF THE CYP1A2 INHIBITOR FLUVOXAMINE ON TACRINE PHARMACOKINETICS IN HUMANS
Authors: BECQUEMONT L RAGUENEAU I LEBOT MA RICHE C FUNCKBRENTANO C JAILLON P
Citation: L. Becquemont et al., INFLUENCE OF THE CYP1A2 INHIBITOR FLUVOXAMINE ON TACRINE PHARMACOKINETICS IN HUMANS, Clinical pharmacology and therapeutics, 61(6), 1997, pp. 619-627
INFLUENCE OF FLUVOXAMINE ON TACRINE METABOLISM IN-VITRO - POTENTIAL IMPLICATION FOR THE HEPATOTOXICITY IN-VIVO
Authors: BECQUEMONT L LEBOT MA RICHE C BEAUNE P
Citation: L. Becquemont et al., INFLUENCE OF FLUVOXAMINE ON TACRINE METABOLISM IN-VITRO - POTENTIAL IMPLICATION FOR THE HEPATOTOXICITY IN-VIVO, Fundamental and clinical pharmacology, 10(2), 1996, pp. 156-157
INHIBITION OF CYP1A2 AND CYP3A4 BY OLTIPRAZ RESULTS IN REDUCTION OF AFLATOXIN B-1 METABOLISM IN HUMAN HEPATOCYTES IN PRIMARY CULTURE
Authors: LANGOUET S COLES B MOREL F BECQUEMONT L BEAUNE P GUENGERICH FP KETTERER B GUILLOUZO A
Citation: S. Langouet et al., INHIBITION OF CYP1A2 AND CYP3A4 BY OLTIPRAZ RESULTS IN REDUCTION OF AFLATOXIN B-1 METABOLISM IN HUMAN HEPATOCYTES IN PRIMARY CULTURE, Cancer research, 55(23), 1995, pp. 5574-5579
VARIABLE DISPOSITION KINETICS AND ELECTROCARDIOGRAPHIC EFFECTS OF FLECAINIDE DURING REPEATED DOSING IN HUMANS - CONTRIBUTION OF GENETIC-FACTORS, DOSE-DEPENDENT CLEARANCE, AND INTERACTION WITH AMIODARONE
Authors: FUNCKBRENTANO C BECQUEMONT L KROEMER HK BUHL K KNEBEL NG EICHELBAUM M JAILLON P
Citation: C. Funckbrentano et al., VARIABLE DISPOSITION KINETICS AND ELECTROCARDIOGRAPHIC EFFECTS OF FLECAINIDE DURING REPEATED DOSING IN HUMANS - CONTRIBUTION OF GENETIC-FACTORS, DOSE-DEPENDENT CLEARANCE, AND INTERACTION WITH AMIODARONE, Clinical pharmacology and therapeutics, 55(3), 1994, pp. 256-269
IMPROVEMENT OF ARTERIAL COMPLIANCE BY A C ONVERTING-ENZYME-INHIBITOR IN PATIENTS WITH LOWER-EXTREMITIES ARTERIAL-DISEASE
Authors: LAURENT S BECQUEMONT L LALOUX B ASMAR R HUGUE C VAYSSAIRAT M BILLAUD E BAUTHIER P COHEN N HOURI L RENAUDIN JM TAIEB N SAFAR M
Citation: S. Laurent et al., IMPROVEMENT OF ARTERIAL COMPLIANCE BY A C ONVERTING-ENZYME-INHIBITOR IN PATIENTS WITH LOWER-EXTREMITIES ARTERIAL-DISEASE, Archives des maladies du coeur et des vaisseaux, 87(8), 1994, pp. 987-990
EXPRESSION OF PLASMINOGEN PLASMIN RECEPTORS ON HUMAN GLOMERULAR EPITHELIAL-CELLS/
Authors: BECQUEMONT L NGUYEN G PERALDI MN HE CJ SRAER JD RONDEAU E
Citation: L. Becquemont et al., EXPRESSION OF PLASMINOGEN PLASMIN RECEPTORS ON HUMAN GLOMERULAR EPITHELIAL-CELLS/, The American journal of physiology, 267(2), 1994, pp. 60000303-60000310
Risultati: 1-9 |